ArticleJournal of clinical laboratory analysis2025
Epithelial-Mesenchymal Transition States and Metabolic Reprogramming Related Signatures Predict Prognosis and Therapeutic Responses in HER2-Positive Breast Cancer.
Article in Journal of clinical laboratory analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundEpithelial-mesenchymal transition (EMT) and metabolic reprogramming have been shown to regulate HER2 targeted therapy resistance and tumor metastasis. We aimed to establish an EMT-associated and metabolic-related prognostic model in HER2-positive breast cancer.
methodsmRNA expression and clinical information for HER2-positive breast cancer are downloaded from the TCGA database. The single sample gene set enrichment analysis score was used to generate EMT subtypes and identify EMT-related metabolic pathways. A prognostic risk score was developed based on the differentially expressed genes (DEGs) of the EMT-associated metabolic pathways using least absolute shrinkage and selection operator (LASSO) Cox regression and then validated in an external cohort (GSE96058).
resultsThe EMT enriched scores differentiated the OS in the HER2-positive breast cancer TCGA cohort (p = 0.023; HR, 0.38; 95% CI, 0.16-0.9), which was also associated with the carbohydrate, amino acid, nucleotide, and tricarboxylic acid (TCA) cycle pathways (p < 0.05). A total of 10 genes based on the DEGs between the metabolic groups were used to construct the prognosis model. Patients with low-risk metabolic scores showed longer OS compared to those with high-risk metabolic scores (p < 0.001; HR, 0.09; 95% CI, 0.03-0.31). The association between OS and the metabolism score remained significant in the multivariable Cox regression (p < 0.001; HR, 0.08; 95% CI, 0.03-0.22). Similar results were observed in the validation cohort (p = 0.002; HR, 0.34; 95% CI, 0.16-0.69).
conclusionEMT and metabolic reprogramming-related features are specific prognostic and potential therapeutic biomarkers for HER2-positive breast cancer patients, which warrant further studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.